Targets › GPR109A
1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Apr 2027.
Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. (UniProt, Q8TDS4)
Open in Phaseline: the race on GPR109A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Albert Einstein College of Medicine | Nicotinic acid GPR109A receptor agonist; induces vasodilation and affects lipid metabolism | GPR109A | Phase 2 | Diabetes Mellitus | Apr 2027 |
Diabetes Mellitus (1)
small molecule (1)
Albert Einstein College of Medicine (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.